Advancing Cytotoxicity Assays to Strengthen Early CAR-T Development Decisions
- Leveraging real-time monitoring to enable tumor rechallenge experiments and deeper insight into CAR-T cytotoxic durability and functional exhaustion
- Identifying clinical correlates for preclinical assay results to ensure streamlined Phase I clinical testing
- Applying dynamic assay data to better characterize the cytotoxic profile of final CAR-T products and support confident preclinical-to–Phase I translation